Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points

Trial Profile

Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Gastric cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2017 Status changed from recruiting to active, no longe recruiting, according to results presented at the 2017 Gastrointestinal Cancers Symposium.
    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.
    • 28 Apr 2014 Status changed from planning to recruiting as rported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top